Cargando…

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Wenbo, Li, Caixia, Tang, Jun, Song, Jinlong, Li, Zixiang, Sun, Jize, Xu, Yili, Zheng, Zhaomin, Cao, Jingqin, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875237/ https://www.ncbi.nlm.nih.gov/pubmed/31819623 http://dx.doi.org/10.2147/CMAR.S217524

Ejemplares similares

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Liu, Baojiang, et al.
Publicado: (2019)

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization
por: Wu, Yanfang, et al.
Publicado: (2022)

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis
por: Chen, Shiguang, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Li, Weiwei, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma
por: Yang, Yanjie, et al.
Publicado: (2023)

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
por: Feng, Ai-Wei, et al.
Publicado: (2022)

The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
por: Sun, Bo, et al.
Publicado: (2022)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Lin, et al.
Publicado: (2018)

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review
por: Manjunatha, Nisha, et al.
Publicado: (2022)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study
por: Guo, Wenbo, et al.
Publicado: (2020)

Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma
por: Kong, Jie-Yu, et al.
Publicado: (2018)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)

The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer
por: Bi, Yonghua, et al.
Publicado: (2022)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma with Child-Pugh B7
por: Jiang, Jian-Qiang, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results
por: Bai, Mingjun, et al.
Publicado: (2019)

Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization
por: Liu, Chang, et al.
Publicado: (2017)

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
por: He, MinKe, et al.
Publicado: (2019)

Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma
por: Wan, Xuying, et al.
Publicado: (2016)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma
por: Yang, Zhi-Wen, et al.
Publicado: (2018)

Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization
por: Li, Qing, et al.
Publicado: (2018)

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
por: Bi, Yonghua, et al.
Publicado: (2022)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
por: Teng, Ying, et al.
Publicado: (2022)

Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma
por: Lin, Haimin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btbo374fouehf2lfsju1ccfnrj